The patents relate to antibodies that target calcitonin gene-related peptide, a molecule linked to migraines. Teva had argued that the antibodies were discovered after “years of painstaking study” into CGRP for development of its migraine treatment, Ajovy.
Lilly argued that researchers already knew about CGRP and the Teva patents used known techniques for developing antibodies. While it was successful on six of the patents, three others covered a specific method of treatment that would not have had a “reasonable expectation of success,” the three-judge panel of the U.S. Court of Appeals for the Federal Circuit ruled in one of the three opinions covering the nine patents.
To contact the reporter on this story:
To contact the editors responsible for this story:
© 2021 Bloomberg L.P. All rights reserved. Used with permission.